Nephros, Inc. (NEPH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

12.57 k

Shareholding (Mar 2025)

FII

0.41%

Held by 4 FIIs

DII

96.63%

Held by 3 DIIs

Promoter

0.00%

What does Nephros, Inc. do?

22-Jun-2025

Nephros, Inc. is a micro-cap company that develops and sells water purification products for medical and commercial markets, with recent net sales of $5 million and a net profit of $1 million. It has a market cap of $40.07 million and key metrics include a P/E ratio of 36.00 and a return on equity of 8.62%.

Who are in the management team of Nephros, Inc.?

22-Jun-2025

As of March 2022, the management team of Nephros, Inc. includes Andrew Astor as President and CEO, alongside Board members Thomas Gwydir, Alisa Lask, Malcom Persen, Oliver Spandow, and Independent Director Arthur Amron.

Is Nephros, Inc. technically bullish or bearish?

25-Jun-2025

As of November 1, 2023, there is insufficient technical data for Nephros, Inc. to determine a bullish or bearish outlook.

Is Nephros, Inc. overvalued or undervalued?

11-Nov-2025

As of November 7, 2025, Nephros, Inc. is rated very attractive with strong valuation metrics, including a P/E ratio of 36 and a PEG ratio of 0.23, indicating it is undervalued compared to peers like Nutriband, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Positive results for the last 3 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 1.99 MM
NET SALES(HY) At USD 9.3 MM has Grown at 37.23%
NET PROFIT(HY) Higher at USD 0.8 MM

With ROE of 8.62%, it has a attractive valuation with a 3.83 Price to Book Value

High Institutional Holdings at 45.28%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 42 Million (Micro Cap)

P/E

36.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.49

Return on Equity

13.82%

Price to Book

4.34

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Jun 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

39.4%

6 Months

76.91%

1 Year

255.04%

2 Years

161.76%

3 Years

472.77%

4 Years

-16.18%

5 Years

-7.29%

Nephros, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Nephros, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics. Despite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market....

Is Nephros, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison, Nephros has a more favorable PEG ratio of 0.23 compared to its peer Nutriband, Inc., which has a negative P/E ratio and a PEG of 0.0000, indicating a significant valuation gap. While the stock has not provided return data for comparison, its recent valuation improvements suggest a positive outlook. Overall, Nephros, Inc. is positioned as an attractive investment opportunity within the Pharmaceuticals & Biotechnology sector....

Is Nephros, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation metrics. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 0.23, and an EV to EBITDA ratio of 31.89. In comparison, its peer Nutriband, Inc. has a P/E ratio of -11.62, highlighting Nephros's relatively stronger valuation position. Despite recent stock performance showing a significant decline of 19.30% over the past week compared to a 1.63% drop in the S&P 500, Nephros has delivered impressive returns year-to-date at 212.93%, significantly outperforming the S&P 500's 14.40%. This performance, combined with its attractive valuation ratios, suggests that Nephros, Inc. is positioned favorably in the market....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

9.99%

EBIT Growth (5y)

18.67%

EBIT to Interest (avg)

-2.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.40

Sales to Capital Employed (avg)

1.55

Tax Ratio

1.50%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.28%

ROCE (avg)

2.77%

ROE (avg)

1.72%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.83

EV to EBIT

31.89

EV to EBITDA

31.89

EV to Capital Employed

5.73

EV to Sales

2.06

PEG Ratio

0.23

Dividend Yield

ROCE (Latest)

13.86%

ROE (Latest)

8.62%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (2.96%)

Foreign Institutions

Held by 4 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -10.20% vs 25.64% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -66.67% vs 100.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.40",
          "val2": "4.90",
          "chgp": "-10.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.30",
          "val2": "0.60",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "56.10%",
          "val2": "116.10%",
          "chgp": "-6.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 42.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 106.25% vs 65.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.20",
          "val2": "14.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.10",
          "val2": "-1.40",
          "chgp": "107.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.10",
          "val2": "-1.60",
          "chgp": "106.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.40%",
          "val2": "-111.90%",
          "chgp": "11.23%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

4.40

4.90

-10.20%

Operating Profit (PBDIT) excl Other Income

0.30

0.60

-50.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.20

0.60

-66.67%

Operating Profit Margin (Excl OI)

56.10%

116.10%

-6.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -10.20% vs 25.64% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -66.67% vs 100.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

14.20

Operating Profit (PBDIT) excl Other Income

0.10

-1.40

107.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.10

-1.60

106.25%

Operating Profit Margin (Excl OI)

0.40%

-111.90%

11.23%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 42.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 106.25% vs 65.22% in Dec 2023

All Annual Results

Company CV

About Nephros, Inc.

Nephros, Inc.

Pharmaceuticals & Biotechnology

Nephros, Inc. (Nephros), is a commercial-stage company that develops and sells water purification products to medical devices and commercial markets. In medical device markets, its filters are generally classified as ultrafilters, and are used primarily by hospitals for the prevention of infection from water-borne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. In commercial markets, the Company manufactures and sell filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Marketed under both the Nephros and AETHER brands. The Company’s product lines are: Water Filtration Products and Specialty Renal Products (HDF System). The Company’s subsidiary, Specialty Renal Products, Inc. (SRP), is a development-stage medical device company focused primarily on developing hemodiafiltration (HDF) technology.

Company Coordinates

Company Details

380 Lackawanna Pl , SOUTH ORANGE NJ : 07079-1704

Tel: 1 201 3435202

https://www.nephros.com/

Registrar Details

Nephros, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does Nephros, Inc. do?

Watch in Real-Time

Who are in the management team of Nephros, Inc.?

Is Nephros, Inc. technically bullish or bearish?

Is Nephros, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

The company has declared Positive results for the last 3 consecutive quarters

With ROE of 8.62%, it has a attractive valuation with a 3.83 Price to Book Value

High Institutional Holdings at 45.28%

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Nephros, Inc. overvalued or undervalued?

Is Nephros, Inc. overvalued or undervalued?

Is Nephros, Inc. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Nephros, Inc.

Company Coordinates